- (pronunciation: kwi NYOO pris tin / dal FOE pris tin) (trade name
Synercid) is a
combination of two
antibiotics used to
treat infections by staphylococci...
-
managed to halt an
epidemic of VRE.
Although quinupristin/dalfopristin (
Synercid) was
previously indicated for
treatment of VRE in the USA, the FDA approval...
- (marketed
under the
trade name
Synercid) was
brought to the
market by Rhone-Poulenc
Rorer Pharmaceuticals in 1999.
Synercid (weight-to-weight
ratio of 30%...
- antibiotic, used in
combination with
dalfopristin under the
trade name
Synercid. It has
activity against Gram-positive and
atypical bacteria but not Gram-negative...
- (INN)
Symmetrel Synacort Synagis Synalar Synalgos-DC
Synarel Syncurine Synercid Synkayvite Synophylate Synovalyte Synphasic Synthroid Syntocinon Syprine...
-
development of the pristinamycin-derivative quinupristin/dalfopristin (i.e.,
Synercid),
which may be
administered intravenously for more
severe MRSA infections...
-
inhibition of
protein synthesis Platensimycin Quinupristin/Dalfopristin
Synercid Thiamphenicol Gram-negative, Gram-positive, anaerobes.
Widely used in veterinary...
- infections)
Quadracel (DTaP-IPV/Hib vaccine)
Shanchol (Cholera vaccine)
Synercid (Quinupristin/dalfopristin),
marketed by Pfizer.
Tenivac (Tet**** vaccine)...
-
oritavancin (Orbactiv), and
telavancin (Vibativ); quinupristin/dalfopristin (
Synercid, a
combination of two streptogramins, not
active against E. faecalis);...
- when
administered in a 3:7 ratio,
comprise the 1999 FDA
approved drug
Synercid. Mukhtar, T.A.; Wright, G.D. (2005). "Streptogramins, oxazolidinones, and...
